{"id":"NCT00690573","sponsor":"Abbott","briefTitle":"Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis","officialTitle":"A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-03","completion":"2011-09","firstPosted":"2008-06-04","resultsPosted":"2011-04-01","lastUpdate":"2012-09-10"},"enrollment":25,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["adalimumab, ABT-D2E7, Humira"]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis","primaryOutcome":{"measure":"Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Adalimumab","deltaMin":23,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":["30054164","23053683"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":25},"commonTop":["nasopharyngitis","upper respiratory tract infection","influenza","pharyngitis","gastroenteritis"]}}